Nous apportons une aide vitale d’urgence aux populations touchées par des catastrophes ou des conflits. À plus long terme, nous les aidons à cultiver ou acheter de quoi se nourrir et assurer leur survie et celle de leur famille. A tout moment, nos équipes interviennent sur près de 30 opérations d'urgences à travers le monde.
Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries.
This paper argues that European Union trade policies should not be used to bolster pharmaceutical companies’ profits by extending their monopolies on medicine prices to supposedly reward research. Instead, the incoming European Commission must defend a trade and R&D model that is coherent with its development and public health objectives, and that supports innovative R&D models that create new, affordable medicines.
This should begin by ensuring that the ‘regulatory harmonization’ to be enshrined in the Transatlantic Trade and Investment Partnership will not lock in regulations that serve corporate interests over those of the public, setting new global standards that will later be imposed on developing countries.
For more on this, read Oxfam and HAI Europe’s original briefing: Trading Away Access to Medicines: How the European Union’s trade agenda has taken a wrong turn